On ECHEMI
Home > Drugs > Jiangsu Nhwa Pharmaceutical Co., Ltd.
Jiangsu Nhwa Pharmaceutical Co., Ltd.
  • Founded in:

    1999-03-29
  • Country:

    China China
  • Address:

    No. 18, Yangshan Road, Xuzhou Economic and Technological Development Zone
  • Tax NO.:

    913203001363846728
  • Registered Funds:

    1016.176792 million yuan
  • Website:

  • Email:

Related Drugs
Midazolam Injection
Name Description Content CAS NO. Registered Holders
Midazolam

No specific description provided

More

No specific description provided

0
Naproxen Extended Release Capsules
The main ingredient of this product: naproxen. Chemical name ()-methyl-6-methoxy-2-naphthylacetic acid, molecular formula C14H14O3, molecular weight 230.26.
Name Description Content CAS NO. Registered Holders
Naproxen

This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

More

This product is a non-steroidal anti-inflammatory drug. Its analgesic, anti-inflammatory and antipyretic effects work by inhibiting the synthesis of prostaglandins.

22204-53-1 30
Riluzole Tablets
The main ingredient of this product is riluzole, and its chemical name is: 2-chloro-6-trifluoromethoxybenzothiazole.
Name Description Content CAS NO. Registered Holders
Riluzole

The pharmacokinetics of riluzole were evaluated after single oral doses of 25 to 300 mg and repeated oral doses of 25 to 100 mg twice daily. The increase in blood concentration levels is linearly related to the dose. Its pharmacokinetic properties are non-dose dependent. When repeated doses are administered (50 mg riluzole tablets, twice a day, for a ten-day course of treatment), the original riluzole accumulates in the plasma to twice the single dose and reaches a steady state within 5 days.

More

The pharmacokinetics of riluzole were evaluated after single oral doses of 25 to 300 mg and repeated oral doses of 25 to 100 mg twice daily. The increase in blood concentration levels is linearly related to the dose. Its pharmacokinetic properties are non-dose dependent. When repeated doses are administered (50 mg riluzole tablets, twice a day, for a ten-day course of treatment), the original riluzole accumulates in the plasma to twice the single dose and reaches a steady state within 5 days.

1744-22-5 10
Flumazenil
Name Description Content CAS NO. Registered Holders
Flumazenil

Extract from the above information

More

Extract from the above information

78755-81-4 21
Paracetamol and aspirin caffeine tablets
Name Description Content CAS NO. Registered Holders
Salicylphenol

0
2-Picoline

109-06-8 0
Caffeine

0
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.